Skip to main navigation
Skip to search
Skip to main content
Mayo Clinic Home
Search content at Mayo Clinic
Home
Profiles
Departments/Divisions
Grants
Research output
Prizes
Pneumocystis pneumonia in patients treated with rituximab
Isabel Martin-Garrido
,
Eva M. Carmona
,
Ulrich Specks
,
Andrew H. Limper
Pulmonary and Critical Care Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
106
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Pneumocystis pneumonia in patients treated with rituximab'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Rituximab
100%
Pneumocystis Jirovecii
100%
Clinical Course
27%
Mayo Clinic
9%
Rochester
9%
Cytotoxic Chemotherapy
9%
Clinical Presentation
9%
Hematological Malignancies
9%
T Cell Immunity
9%
Underlying Disease
9%
Chemotherapy Regimen
9%
Rituximab Therapy
9%
B Lymphocytes
9%
Pneumocystis
9%
Support Roles
9%
Computer Search
9%
Secondary Prophylaxis
9%
Immune Reconstitution
9%
Concomitant Chemotherapy
9%
Primary Prophylaxis
9%
ICU Admission
9%
Risk Potential
9%
Opportunistic Fungal Infections
9%
Acute Hypoxemic Respiratory Failure
9%
During Treatment
9%
Possible Risk Factors
9%
Glucocorticoid Exposure
9%
Medicine and Dentistry
Pneumocystis Pneumonia
100%
Rituximab
100%
Disease Course
27%
Glucocorticoid
27%
Cellular Immunity
9%
Respiratory Failure
9%
Systematic Review
9%
Cytotoxic Chemotherapy
9%
Mycosis
9%
Hematologic Malignancy
9%
B Lymphocyte
9%
Fulminant
9%
Isoniazid
9%
Immune Reconstitution
9%
Diseases
9%
Chemotherapy
9%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
100%
Pneumocystis Pneumonia
100%
Disease Course
27%
Glucocorticoid
27%
Respiratory Failure
9%
Cytotoxic Chemotherapy
9%
Chemotherapy Regimens
9%
Hematologic Malignancy
9%
Mycosis
9%
Isoniazid
9%
Pneumocystis
9%
Diseases
9%